Health Evidence Network synthesis report 53
Int J Vaccines Vaccin 2016, 2(1): 00018, January 29, 2016
nContraception and Reproductive Medicine (2017) 2:26 DOI 10.1186/s40834-017-0053-6
Young women in Burkina Faso and Mali are increasingly using modern contraceptives for family planning; however, the LAPM contraceptive prevalence rate remains low. Our analysis indicates that social norms around idea...l family size for both men and women continue to drive young women’s choices around family planning and impede use of LAPMs. To increase modern contraceptive use and curb fertility rates, local governments and development organizations should focus on women’s empowerment and include male partners.
more
The story-book, a sequel to the immensely successful ‘My Hero is You: How kids can fight COVID-19!’, is being released in the second year of the COVID-19 pandemic. The new story, aimed primarily at children aged 6-11 years, sees the return of Ario, a fantasy creature who travels the world helpin...g children find hope in the future and joy in simple pleasures. Together with old and new friends, Ario addresses the fears, frustrations and concerns faced by children during this phase of the pandemic and explores with them the various coping mechanisms that they can use when faced with difficult emotions like fear, grief, anger and sadness. Through the voices of the children that Ario meets on his travels, the book provides a vivid illustration of the impact of COVID-19 on the mental health and well-being of children.
The content of the book drew from survey responses from more than 5000 children, parents, caregivers and teachers from around the world on the challenges they continue to face in the second year of the pandemic.
Available in different languages
more
Le HCSP a fondé ses recommandations sur les connaissances actuellement disponibles en particulier les publications scientifiques relatives au COVID-19 mais aussi de recommandations relatives à la prise en charge des pneumonies post grippales, et des pneumonies sévères en réanimation.
Cet avi...s du HCSP délivre également des indications sur la prise en charge non spécifique, et de possibles thérapeutiques antivirales, dans l’attente de la mise en place d’essais thérapeutiques académiques afin de progresser dans la connaissance de la maladie. Ces recommandations relatives aux traitements spécifiques seront adaptées en fonction des résultats des essais cliniques lorsqu’ils seront disponibles.
more
Non-pharmaceutical interventions (NPI) are public health measures that aim to prevent and/or control SARS-CoV-2 transmission in the community. As long as there is no effective and safe vaccine to protect those at risk of severe COVID-19, NPI are the most effective public health interventions against... COVID-19. These ECDC guidelines detail available options for NPI in various epidemiologic scenarios, assess the evidence for their effectiveness and address implementation issues, including potential barriers and facilitators.
more
Au Mali, près de huit millions de filles et de femmes ont subi des MGF. À l’échelle nationale, 89 % des filles et des femmes âgées de 15 à 49 ans ont subi cette pratique. À l’échelle infranationale, cette proportion varie de 96 % dans la région de Sikasso à moins de 1 % dans les régio...ns de Gao et Kidal.
more
Most African Countries Avoid Major Economic Loss but Impact on Guinea, Liberia, Sierra Leone Remains Crippling
Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?
Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera...lly in middle age. Acute coronary and cerebrovascular events frequently occur suddenly, and are often fatal before medical care can be given. Modification of risk factors has been shown to reduce mortality and morbidity in people with diagnosed or undiagnosed cardiovascular disease.
This publication provides guidance on reducing disability and premature deaths from coronary heart disease, cerebrovascular disease and peripheral vascular disease in people at high risk, who have not yet experienced a cardiovascular event. People with established cardiovascular disease are at very high risk of recurrent events and are not the subject of these guidelines. They have been addressed in previous WHO guidelines.
Several forms of therapy can prevent coronary, cerebral and peripheral vascular events. Decisions about whether to initiate specific preventive action, and with what degree of intensity, should be guided by estimation of the risk of any such vascular event. The risk prediction charts that accompany these guidelinesb allow treatment to be targeted accord-
ing to simple predictions of absolute cardiovascular risk.
Recommendations are made for management of major cardiovascular risk factors through changes in lifestyle and prophylactic drug therapies. The guidelines provide a framework for the development of national guidance on prevention of cardiovascular disease that takes into account the particular political, economic, social and medical circumstances.
more
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens.
Results are used to inform A...RT programme decision making regarding optimal ART regimens and support evaluation of programme quality with respect to maximizing viral load suppression and minimizing emergence of resistance in people taking ART.
more
UNAIDS and DPKO non paper | 2011
The limitation of a single sector approach. HNP Discussion Paper
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
DHS Further Analysis Reports No. 101
This document is to guide policy makers, managers, districts, health workers, communities, NGOs and all other stakeholders on how to implement newborn health services.